European Society for Medical Oncology
European Society for Medical Oncology
Phase III SAFFRON data show osimertinib plus savolitinib cut progression or death risk by 45% and death risk by 32% versus chemotherapy in MET-driven epidermal growth factor receptor-mutated non-small cell …
Phase 3 data for Merck & Co. and Moderna’s personalized mRNA cancer vaccine intismeran autogene were presented at ESMO’s Presidential Symposium in Madrid, days after a pre-conference data leak.
You must be logged in to post a comment.